维立志博-B（09887）发布公告，公司于2025年10月16日与Dianthus Therapeutics, Inc.签订全球独家许可协议，双方将共同推进临床前资产及新型抗BDCA2-TACI双特异性融合蛋白LBL-047的开发。LBL-047已获得美国新药临床试验（IND）许可及中国内地IND受理。
根据协议，Dianthus将获得在大中华区以外地区研发、生产及商业化LBL-047的全球独家权益。南京维立志博将获得最高3800万美元的首付款，以及潜在的里程碑付款，总额可达10亿美元。南京维立志博还将有权获得大中华区以外地区净销售额的分级特许权使用费，费率从中个位数至低双位数不等。
此次合作将有助于南京维立志博在自身免疫疾病治疗领域的创新药物开发，进一步加强公司在该领域的市场地位。需要注意的是，公司无法保证LBL-047的成功开发或最终上市，股东及潜在投资者在交易时需谨慎。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.